 |
 Trading
Alert: Biophan Technologies |
|
|
  If
you don’t currently know someone with a pacemaker, cardiac stent or other
implanted medical device, you will. That person may even be you.
As the population ages, one thing
is irrefutable: more implanted medical devices will be needed. But
there’s a big problem. Life-saving Magnetic Resonance Imaging (MRI)
procedures which are routinely utilized to quickly detect serious disease,
are virtually unavailable to patients with an implanted metal or electronic
device.
 Problem
solved…and more.
New York-based Biophan Technologies
(OTCBB:
BIPH) has developed—and patented-- solutions to this serious medical
challenge. (See Press release attached). Biophan develops and markets technologies
used to make biomedical devices—such as cardiac pacemakers, surgical and
diagnostic tools, safe and compatible with MRI equipment and other sources
of powerful magnetism or radio frequency signals.
Accumulation of the company’s
shares at these levels by risk oriented investors is recommended for significant
gains over the next 12 months and beyond.
 For
the technically adept, the above chart shows a 50% price retracement (shares
currently 37 cents) following Biophan’s November 2003 run-up and looks
to be forming a continued uptrend with opportunistic entry points. A break
above 50 cents would confirm the uptrend. Risk-oriented investors should
consider accumulating shares up to the 50-cent level in anticipation of
significant gains over the next 12 months. A stop at 25 cents would likely
be prudent, but perhaps for only half of a position. This stock is volatile.
On November 4th 2003, when
BIPH announced its collaboration with Boston Scientific (see below). As
a result, the stock traded over 8 million shares and the price rose
from 20 cents to north of 40 cents that day-- in excess of a 100-percent
return. This company’s progress is obviously news driven and there
are likely significant developments to come, making the shares attractive
for both short-term traders and long-term investors.
Biophan bullet points:
-
12 month trading range of 10 cents to
$1.15
-
Shares outstanding 46 million. Float
33 million.
-
Market cap $17 million.
-
Biophan’s proprietary, patented products
include coatings, filters and photonics that significantly minimize the
problems experienced to date between MRI electromagnetic fields and interventional
as well as implanted devices.
-
Pacemaker market $4 billion plus and
growing
-
Medical device—stents, wires, clips,
etc, market: $3 billion plus and growing.
-
Exclusive licenses for 3 US issued patents
from Johns Hopkins University. Fifty-five-plus further patents pending.
-
Corporate mandate to continue the construction
of a significant, revenue-generating portfolio of patented biotechnology
intellectual properties.
The potential for the company’s
products to herald significant therapeutic medical advancement is unusually
compelling.
Given the strong annual growth of
both the medical device market and the biotechnology sector, Biophan’s
patented, implanted device coating technology should be of extreme interest
to risk-oriented investors. As should the company’s business focus to develop
and acquire more cutting edge intellectual biotechnology property to enhance
revenues through licensing and joint venture deals.
 Why
Biophan matters to patients and investors:
An MRI is….
MRI uses magnetism to create the
images. Unlike regular x-rays or CT scanning, it does not use x-rays or
any other type of radiation. An MRI machine uses a very large magnet to
create a powerful magnetic field that is used in conjunction with radio
waves. The magnetic field and the radio waves stimulate atoms to give off
tiny radio signals. The length of time for which these response signals
are emitted after an atom is stimulated varies depending upon the body
tissue being examined; different types of body tissue emit signals that
vary in length. A computer analyzes the different signal lengths and generates
cross-sectional images of the body tissues.
Amazing, frankly.
 Who
shouldn’t—or can’t-- have an MRI?
The magnetic field inside the machinery
is so powerful that it can erase credit cards in your wallet, send a metal
object flying, or interfere with the workings of an item such as a pacemaker.
So some people are not candidates for MRI scans because of metallic implants
in their body, such as a pacemaker, any implanted surgical clip, an artificial
joint, a metal plate or screw, or a contraceptive diaphragm as in an intrauterine
device (IUD).
Today, many devices (such as pacemakers
and surgical devices) are not used with MRI due to safety concerns involved
with the MRI environment, including heating of devices and metal wire leads,
which can cause tissue damage.
Number one with a (coated) bullet.
The MRI/medical device initiative
alone would likely be enough for most companies. Not Biophan. This small—for
now—biotech concerns has big plans.
In early November 2003, Biophan struck
a joint development deal with behemoth Boston Scientific (NYSE:
BSX) to make MRI-friendly devices as well as explore licensing
agreements. Although details of the deal weren’t given, even a modest success
in this area would mean that MRI’s could be utilized on many patients who,
due to implanted metal and electronic devices, have been, to date, unable
to benefit from imaging technology.
Discussions with other major medical
device companies are ongoing.
We believe that success in this endeavor
will help millions of current and future patients. Extrapolate that to
other cutting edge biotech products and technologies and Biophan’s potential
is apparent.
If you own it, they will come.
Patents are the currency of business--
particularly technology and biotechnology. As Biophan’s intellectual property
portfolio grows, potential licensees will either seek out—or be sought
out by—the company to utilize its patented technology. As well, Biophan
offers turnkey solutions to customers, including major medical device companies,
providing products and R&D backed up by its world-class biotech personnel.
Investors need only look at the recent
growth of the coated cardiac stent market to get some understanding of
the potential application for Biophan’s products. Companies such as Guidant
(NYSE:
GDT), Medtronic
(NYSE:
MDT) and Angiotech
(NASDAQ:
ANPI) have enjoyed explosive growth as that complimentary therapy
found itself at the forefront of both medical and investor interest.
Making therapies better and safer
is, as Biophan represents, just as important and profitable as the original
discovery itself.
Below is the complete text of Biophan's
news release today for your review. We will continue to follow BIPH’s progress.
| News Release
Investor Relations Contact:
Racquel Rivera, Vice
President
Trilogy Capital Partners,
Inc.
800.330.6540
racquel@trilogy-capital.com
Biophan Technologies Announces 2004
Strategic Initiatives
________________________
Objectives Call for
Further Innovation, Market Expansion and Significant Growth
Rochester, NY, December
19, 2003—Biophan Technologies, Inc. (OTC
BB: BIPH), an innovator, developer, and marketer of advanced biomedical
technology, today announced its Strategic Initiatives for 2004. The
announcement was made by Michael Weiner, Biophan’s CEO.
Mr. Weiner stated, “With
the year drawing to a close and Biophan’s strategic plan being executed,
the company is announcing it strategic initiatives for 2004.”
During 2003 the Company
introduced the following:
Strategic Initiative
1—Acquisition of Intellectual Assets:
Biophan’s leadership
position in its market segment is highly dependent upon continued development
and acquisition of intellectual property. With three United States
patents under license and more than 50 patents pending, the Company is
aggressively pursuing internal research and development projects, as well
as sourcing leading-edge providers of related technologies.
Intellectual property,
such as technology solutions and patents, may be developed internally,
through joint ventures, or purchased. To ensure the continuing value
of their intellectual assets, Biophan will aggressively defend its licenses,
both domestically and abroad.
Strategic Initiative
2—Market Expansion:
Biophan currently enjoys
a leadership position in developing technologies that make implanted medical
devices, such as heart pacemakers, safe for use with MRI and other diagnostic
imaging tools. Biophan has also developed technologies that allow
for the use of interventional MRI, without the heating problems that can
cause tissue damage or imaging problems that obscure the outcome of the
procedures.
Based on discussions
underway with several biomedical device manufacturers, both in the U.S.
and overseas, Biophan plans to expand the use of the technologies it has
developed to make a wider range of devices compatible with MRI. These
technologies reduce radio frequency interference, heating, and induced
voltages. In 2004, the Company will explore opportunities for these
technologies in the prosthetic and surgical tool markets, where the lack
of MRI compatibility negatively impacts investigational and diagnostic
procedures. Discussions with these device manufacturers indicate
a need for, and interest in, solutions to additional problems where Biophan
can develop solutions. Part of Biophan's strategic initiative for
2004 will include expanding its technology offerings to the companies with
which it is already in discussions, or working with. The initiative
in contrast agents is the first entry into the pharmaceutical arena.
Biophan’s Photonic MRI
Microcoil (PMM) is one example of the Company’s expanded technology.
Recent studies indicate up to 85% of heart attacks and strokes may be caused
by vulnerable plaque which may result in thrombosis, and is not easily
detected by other methods. Biophan’s technologies will pinpoint specific
sites where therapies can address the problem. By inserting the PMM
directly into a blood vessel, MRI can provide a detailed look at vulnerable
plaque without injury-causing heating or image degradation.
Another example of Biophan
expanding on the use of existing, licensed technology is NanoView. NanoView
utilizes nanomagnetic particles, a specific type of nanotechnology,
as contrast agents that preferentially bind to tissues of diagnostic interest,
creating improved detail and contrast in MRI diagnostic image processes.
NanoView improves performance in terms of signal intensity and the use
of multiple markers, which broadens the applications of MRI imaging.
Strategic Initiative
3—Strategic Partnerships:
Leveraging these relationships
is vital to Biophan’s mission. By exploiting its established relationships,
such as the recently announced joint development agreement with Boston
Scientific, Biophan not only creates ready sales channels but the Company
also establishes leverage that has far-reaching impact throughout its market
and the investor community.
Biophan has entered into
Non-Disclosure Agreements with the major manufacturers of implanted biomedical
and related devices. Discussions underway with these companies include
strategic partnerships that may include, joint developments, original equipment
manufacturing arrangements and licensing agreements.
Summary
Biophan is positioned
to exploit its market momentum to gain additional intellectual assets,
expand into adjacent markets, cultivate new strategic alliances and fortify
internal management and operations with top quality recruits. This
will help Biophan to achieve revenues, earnings, and shareholder value.
We are enthusiastic about
our early successes and the milestones we have achieved to date.
Most importantly, Biophan looks forward to substantial growth in revenues,
earnings and, ultimately, in shareholder value.
The company is actively
meeting with institutional investors in the financial community and encourages
all prospective investors to review the Company information on its corporate
website: www.biophan.com.
About Biophan Technologies,
Inc.
Biophan Technologies
develops and markets cutting-edge technologies used to make biomedical
devices—such as cardiac pacemakers, surgical and diagnostic tool—safe and
compatible with magnetic resonance imaging (MRI) equipment and other sources
of powerful magnetism or radio frequency signals. Committed to growth
through innovation and developmental leadership, Biophan’s management holds
exclusive licenses for three issued U.S. patents and has filed 51 related
patents that will help establish Biophan products as the standard of care
in each of their markets. For more information, please visit www.biophan.com.
Cautionary Statement
Regarding Forward-Looking Statements
Certain statements included
in this press release may constitute forward-looking statements.
Actual results could differ materially from such statements expressed or
implied herein as a result of a variety of factors including, but not limited
to: the development of Biophan's MRI technologies; the approval of Biophan's
patent applications; the successful implementation of Biophan's research
and development programs; the acceptance by the market of Biophan's products;
competition and the timing of projects and trends in future operating performance,
as well as other factors expressed from time to time in Biophan's periodic
filings with the Securities and Exchange Commission (the "SEC").
As a result, this press release should be read in conjunction with Biophan's
periodic filings with the SEC. The forward-looking statements contained
herein are made only as of the date of this press release, and Biophan
undertakes no obligation to publicly update such forward-looking statements
to reflect subsequent events or circumstances.
Contact:
Investor Relations:
Trilogy Capital Partners,
Inc.
Racquel Rivera, 800-330-6540
racquel@trilogy-capital.com
or
Press Interviews:
Biophan Technologies,
Inc.
Michael Weiner, 585-214-2441 |
|
| If
You Haven't Already, Sign Up For Your FREE
Preferred Membership! |
|
|
 Over
the past year, we’ve brought you 13 Trading
Alerts. If you had invested $1000 in each one, your $13,000 investment
would have grown to $23070, if you had sold, say, Friday November 7th,
to pick a day. That’s a 78 percent return in a less than a year.
The best? Obviously, Cel-Sci. The worst? ThinkPath. If we strip those two
out—the highest and lowest returns--the return on your $11,000 investment
would have been a very respectable 51 percent. Not too shabby.
By comparison, the S&P index
has returned about 20 percent over the last year. The NASDAQ—to which we
also alerted you at the low in March 2003—has returned around 40 percent
in the same period. The NASDAQ Tracker (NASDAQ:
QQQ) did slightly better than its benchmark having risen 45 percent.
Oh yes, we told you about that one, too at $24 in February 2003. Now it’s
$35.
And we’re only looking at Trading
Alerts. I suspect if we included all of our Company Profiles (check
our Track Record), the numbers would likely have been even better.
The
best is yet to come. Sign up NOW!
Joining our NEW Preferred Member
Program is easy and simple. Just follow this quick two-step process:
Opt-in your email address, then, make sure and confirm the request for
confirmation you will receive in your inbox. That’s it! You'll automatically
be in position to start receiving these new special features available
only to Preferred Members!
To subscribe to the preferred member
list, simply click
here. Or, to subscribe by email, send a blank email to scn-preferred-subscribe@delta.levelogic.com.
If there is a problem with the subscription or you do not receive a confirmation
email within 2 hours, go to http://www.smallcapdigest.net/pref-sub.html
and submit your email address.
Got comments, questions or suggestions?
Send 'em on over:
Editor@smallcapdigest.net
|
